Teva Reports Q3 Results and Raises 2026 Outlook
Teva reported Q3 revenue of $4.395 billion and adjusted EPS of $0.86. It raised its 2026 revenue outlook to $16.7 billion–$17.0 billion and adjusted EPS guidance to $1.92–$2.11.
Story updates
Teva Pharmaceutical Industries Ltd. announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $4.395 billion and adjusted earnings per share of $0.86. The company's performance was driven by strong growth in innovative brands such as AUSTEDO, AJOVY, and UZEDY, which saw year-over-year revenue increases of 21%, 61%, and 96% respectively. Despite a decline in global generics revenue, Teva raised its full-year 2026 revenue outlook to a range of $16.7 billion—$17.0 billion and adjusted EPS guidance to $1.92—$2.11.
Management highlighted the company's progress in its "Pivot to Growth" strategy, noting that its biosimilars business is expected to reach its 2027 revenue objective one year early. Additionally, the company reported improvements in its financial profile, including recent debt refinancings and credit rating upgrades to investment grade.